SavedAdd your journal

Journals / Türk Mikrobiyoloji Cemiyeti Dergisi / 2019 / Cilt: 49 - Sayı: 1

Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates

Karbapeneme Dirençli Klebsiella pneumoniae Klinik İzolatlarında Kolistin Direnci

Ceren ÖZKUL KOÇAK
Gülşen HAZIROLAN
Pages
17–23
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The high prevalence of colistin resistance may cause limitations in treatment options in multiple- drug resistant K. pneumoniae infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The limitations of treatment options in carbapenem resistant Klebsiella pneumoniae infections have been related to high morbidity and mortality in recent years.
📊
Key Findings & Data:Method: In the present study, a total of 81 carbapenem- resistant K. pneumoniae, which were isolated from various clinical specimens in Central Laboratory of Hacettepe Universiy Medical Faculty between September 2018-December 2018, were tested against colistin by using broth microdilution method according to the EUCAST standards.
💡
Conclusion & Impact:Conclusion: The high prevalence of colistin resistance may cause limitations in treatment options in multiple- drug resistant K. pneumoniae infections.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The limitations of treatment options in carbapenem resistant Klebsiella pneumoniae infections have been related to high morbidity and mortality in recent years. The wide usage of colistin as the last-line treatment for those infections has led to the development of an increasing resistance to colistin. Method: In the present study, a total of 81 carbapenem- resistant K. pneumoniae, which were isolated from various clinical specimens in Central Laboratory of Hacettepe Universiy Medical Faculty between September 2018-December 2018, were tested against colistin by using broth microdilution method according to the EUCAST standards. Results: Colistin resistance was determined in 39.5% (n=32) of the isolates tested. According to the sample site, 35% of the urine isolates and 56% of the blood isolates were resistant to colistin. Isolates all of the total 3 cerebrospinal fluid samples included in the analysis were also resistant to colistin. Conclusion: The high prevalence of colistin resistance may cause limitations in treatment options in multiple- drug resistant K. pneumoniae infections.

Özet

Amaç: Karbapeneme dirençli Klebsiella pneumoniae ile gelişen enfeksiyonların tedavisinde yaşanan kısıtlılıklar, son yıllarda yüksek morbidite ve mortalite ile ilişkilendirilmiştir. Bu enfeksiyonlarakarşı son seçenek ilaç olarak görülen kolistinin yaygın kullanımı sonucu kolistin direncinde artışgörülmektedir.Yöntem: Bu çalışmada, Eylül 2018-Aralık 2018 tarihleri arasında Hacettepe Üniversitesi TıpFakültesi Merkez Laboratuvarı’nda çeşitli klinik örneklerden izole edilmiş ve karbapenem direncibelirlenmiş 81 K. pneumoniae izolatında kolistine duyarlılık sıvı mikrodilüsyon yöntemiyle EUCASTstandartlarına göre belirlenmiştir.Bulgular: Test edilen izolatların %39.5’inde (n=32) kolistin direnci saptanmıştır. İdrar izolatlarının%35’i, kan izolatlarının %56’sı kolistin dirençli bulunmuştur. Çalışmaya dâhil edilen 3 beyin omurilik sıvısı örneği de kolistin dirençli olarak belirlenmiştir.Sonuç: Yüksek kolistin direnç oranları çoklu ilaç dirençli K. pneumoniae enfeksiyonlarının tedavilerinde sorun yaşanmasına neden olacaktır.

🔖

Cite This Article

KOÇAK, C. Ö., HAZIROLAN, G. (2022). Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates. Türk Mikrobiyoloji Cemiyeti Dergisi, Cilt: 49 - Sayı: 1, 17–23. https://ajindex.com/articles/635804

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Pereira GH, Garcia DO, Mostardeiro M, Fanti KS, Levin AS. Outbreak of carbapenem-resistant Klebsiella pneumoniae: two-year epidemiologic follow-up in a tertiary hospital. Mem Inst Oswaldo Cruz. 2013;108(1):113-5.
  2. Maltezou HC. Metallo-beta-lactamases in Gramnegative bacteria: introducing the era of panresistance? Int J Antimicrob Agents. 2009;33(5):405 e1-7.
  3. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228-36.
  4. Pitout JD, Nordmann P, Poirel L. Carbapenemaseproducing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents and Chemother. 2015;59(10):5873-84.
  5. Pitout JD, Laupland KB. Extended-spectrum betalactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159- 66.
  6. World Health Organization. Antimicrobial resistance global report on surveillance. 2014. https://www.who. int/drugresistance/documents/surveillancereport/en/ (Erişim tarihi: Aralık 2018)
  7. World Health Organization. Central asian and eastern european surveillance of anrimicrobial resistance (CAESAR), Annual report. 2018 http://www.euro.who. int/en/health-topics/disease-prevention/ antimicrobial-resistance/publications/2017/centralasian-and-eastern-european-surveillance-ofantimicrobial-resistance.-annual-report-2017-2018 (Erişim tarihi: Aralık 2018)
  8. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-41.
  9. Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. Agents of last resort: Polymyxin resistance. Infect Dis Clin North Am. 2016;30(2):391-414.
  10. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011;69(4):357-62.
  11. Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat. 2010;13(4-5):132-8.
  12. Liu YY, Wang Y, Walsh TR, e